- Home
- VCSA vs GDTC Comparison
VCSA vs GDTC Comparison
Compare VCSA & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCSA
- GDTC
- Stock Information
- Founded
- VCSA 2009
- GDTC 2018
- Country
- VCSA United States
- GDTC Singapore
- Employees
- VCSA N/A
- GDTC N/A
- Industry
- VCSA Computer Software: Prepackaged Software
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- VCSA Technology
- GDTC Health Care
- Exchange
- VCSA Nasdaq
- GDTC Nasdaq
- Market Cap
- VCSA 38.6M
- GDTC 33.4M
- IPO Year
- VCSA N/A
- GDTC 2023
- Fundamental
- Price
- VCSA $3.75
- GDTC N/A
- Analyst Decision
- VCSA Buy
- GDTC Buy
- Analyst Count
- VCSA 4
- GDTC 1
- Target Price
- VCSA $6.08
- GDTC $5.00
- AVG Volume (30 Days)
- VCSA 71.4K
- GDTC 26.6K
- Earning Date
- VCSA 11-07-2024
- GDTC 01-01-0001
- Dividend Yield
- VCSA N/A
- GDTC N/A
- EPS Growth
- VCSA N/A
- GDTC N/A
- EPS
- VCSA N/A
- GDTC N/A
- Revenue
- VCSA $949,936,000.00
- GDTC $330,254.00
- Revenue This Year
- VCSA N/A
- GDTC $14.71
- Revenue Next Year
- VCSA N/A
- GDTC N/A
- P/E Ratio
- VCSA N/A
- GDTC N/A
- Revenue Growth
- VCSA N/A
- GDTC N/A
- 52 Week Low
- VCSA $2.07
- GDTC $1.20
- 52 Week High
- VCSA $11.70
- GDTC $5.50
- Technical
- Relative Strength Index (RSI)
- VCSA 48.26
- GDTC 52.17
- Support Level
- VCSA $3.27
- GDTC $2.25
- Resistance Level
- VCSA $4.79
- GDTC $2.65
- Average True Range (ATR)
- VCSA 0.40
- GDTC 0.35
- MACD
- VCSA -0.12
- GDTC -0.04
- Stochastic Oscillator
- VCSA 18.42
- GDTC 30.00
About VCSA Vacasa Inc.
Vacasa Inc is a vacation rental management platform in North America, transforming the vacation rental experience by integrating purpose-built technology with expert local and national teams.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.